Wednesday, July 8, 2026

pharma · Stargardt Disease · Muscle Relaxation · ELTP

ELITE PHARMACEUTICALS INC

ELITE PHARMACEUTICALS INC clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Northvale, USA HQ
1996 Founded
64 Employees
Public company Type
ELTP · NYSE Ticker
Company details
Intelligence · Clinical Programs

ELITE PHARMACEUTICALS INC projects

5 ClinicalTrials.gov programs sponsored by ELITE PHARMACEUTICALS INC.

ELITE PHARMACEUTICALS INC has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial
  2. LBS-008-CT05

    ELITE PHARMACEUTICALS INC /NV/

    Geographic Atrophy

    phase 3 small molecule active

    1 trial
  3. Oxycodone Naltrexone (a)

    ELITE PHARMACEUTICALS INC /NV/

    Pain

    phase 3 small molecule completed

    1 trial
  4. Oxycodone/Naltrexone Capsules

    ELITE PHARMACEUTICALS INC /NV/

    Withdrawal Symptoms

    phase 3 small molecule completed

    1 trial
  5. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ELITE PHARMACEUTICALS INC have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.